Brad Smith rumored as new leader of CMS Innovation Center

Amy Baxter | | Health Exec | Management

Brad Smith is the rumored new leader of CMS’ innovation center, the Center for Medicare and Medicaid Innovation (CMMI), Politico reported.

Smith would take the reins after former director Adam Boehler left his role to become Chief Executive Officer of the U.S. International Development Finance Corporation (DFC) – a new U.S. Government agency. He was confirmed to the new role by the U.S. Senate in September 2019.

Politico cited three sources, noting that CMS declined to comment that Smith was the next director. CMS career staffer Amy Bassano has been acting director of CMMI since Boehler’s departure. Smith was a co-founder of palliative care company Aspire Health, which was sold for an estimated $440 million to Anthem last year.

See the full story below:

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.